A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

NCT02806648 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neuroendocrine Cancer

Interventions

DRUG: Palbociclib

Sponsor

Grupo Espanol de Tumores Neuroendocrinos